Momenta Pharmaceuticals Eyes 1-Yr High Pre-Bell

Momenta Pharmaceuticals Eyes 1-Yr High Pre-Bell

Momenta Pharmaceuticals shares were higher 4% in recent pre-market trade after the company reiterated its guidance for Q4 of 2016 and announced a license deal late Thursday. MNTA was at $16.05 recently, the highest since late 2015 if it holds into regular trading. The current 52-week range is between $7.86 and $15.90. The firm expects non-GAAP operating expenses of approximately $40 million to $45 million and to report $350 million […]

Read More ˃